Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Healthcare Drug Manufacturers - Major Cannabis
Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Aphria Inc.
Bullboard Posts
User Avatar Image
(4)
•••
Comment by maypeterson Dec 04, 2018 12:35am
143 Views
Post# 29058844

RE:RE:It's clear Aphria did some shady stuff

RE:RE:It's clear Aphria did some shady stuff
PeterMacd2 wrote: I I would not trust an unverified report - any report, for or against a stock - at face value.  Especially when the authors have a confessed conflict of interest. 

Only a point-by-point rebuttal and full explanation from the Board & Executive will be better.



The company sure did a good job giving a point-by-pint rebuttal. What a lame response. Probably because they have nothing to say. 


* Do not hold any weed stocks but the research by the shorter is pretty thorough
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities